ClinicalTrials.gg
CompletedNCT03607422Updated Jun 2, 2026Results posted

A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2)

A Phase 3 interventional study of Placebo for Upadacitinib and Upadacitinib in Atopic Dermatitis, sponsored by AbbVie. Completed at 196 sites in 23 countries. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-02.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
912
Allocation
Randomized
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing upadacitinib in Dermatitis, Atopic — 2 open to participants now, 6 under way, 4 of them phase 3. upadacitinib · Dermatitis, Atopic.

Enrollment
3rd of 17
912 · median 272
Started
2018
with 3 others
Phase 3
12 of 17
none open now
Registered
4th of 17
by date
Lead sponsor
15 of 17
AbbVie

Among the 17 studies testing upadacitinib in Dermatitis, Atopic, this one is the 3rd largest by enrollment, is one of 4 that started in 2018, is one of 12 in phase 3, and was the 4th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 17 studies testing upadacitinib in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing upadacitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

Read the detailed description

This study includes a 35-day screening period, a 16-week double-blind period, a blinded extension period up to Week 260, and a 30-day follow-up visit.

Participants who meet eligibility criteria in the main study will be randomized in a 1:1:1 ratio to receive a daily oral dose of upadacitinib 30 mg or upadacitinib 15 mg or matching placebo. Upon completion of enrollment of a minimum of 810 participants in the main study, a supplemental study will continue to enroll adolescents (adolescent sub-study) until a total of 180 adolescent participants are enrolled overall (main study + adolescent sub-study).

Randomization in the main study will be stratified by baseline disease severity (validated Investigator Global Assessment scale for Atopic Dermatitis [vIGA-AD] score of moderate [3] versus severe [4]), by geographic region (United States [US]/Puerto Rico/Canada, and Other), and by age (adolescent [ages 12 to 17] versus adult [ages 18 to 75]). The separate randomization for the adolescent sub-study will be stratified by baseline disease severity (moderate [vIGA-AD = 3] vs. severe [vIGA-AD = 4]) and by geographic region (US/Puerto Rico/Canada and Other).

At Week 16 of the main study and the adolescent sub-study, participants in the placebo group will be re-randomized in a 1:1 ratio to receive daily oral doses of upadacitinib 30 mg or upadacitinib 15 mg in the blinded extension period. In the main study the re-randomization at Week 16 will be stratified by Week 16 50% improvement in Eczema Area and Severity Index [EASI 50] responder [Yes/No], geographic region [US/Puerto Rico/Canada, and other], and age group [adolescent/adult]. For the adolescent sub-study, the re-randomization will be stratified by EASI 50 responder (Yes/No) and by geographic region (US/Puerto Rico/Canada and Other). Participants originally randomized to upadacitinib will continue upadacitinib in the extension period at the same dose.

Starting at the Week 4 visit, rescue treatment for AD may be provided at the discretion of the investigator if medically necessary.

The Primary Analysis for the main study will be conducted after all ongoing participants have completed Week 16. In addition, a Primary Analysis for the adolescent population (including the adolescent participants from the main study and the adolescent sub-study) will be conducted after all ongoing adolescent participants have completed Week 16.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic Dermatitis
  • Upadacitinib
  • ABT-494
  • Measure Up 2
04

Who can participate

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight of ≥ 40 kg at Baseline Visit for participants ≥ 12 and \< 18 years of age
  • Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years prior to Baseline and subject meets Hanifin and Rajka criteria
  • Active moderate to severe AD defined by Eczema Area and Severity Index (EASI) ≥ 16, validated Investigator's Global Assessment (vIGA) ≥ 3, body surface area (BSA) affected by AD ≥ 10%, and weekly average of daily Worst Pruritus numerical rating scale (NRS) score ≥ 4.
  • Candidate for systemic therapy or have recently required systemic therapy for AD
  • Documented history (within 6 months prior to Baseline) of inadequate response to topical (TCS) or topical calcineurin inhibitor (TCI) or documented systemic treatment for AD or for whom topical treatments are otherwise medically inadvisable due to side effects or safety risks

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to any Janus kinase (JAK) inhibitor
  • Unable or unwilling to discontinue current AD treatments prior to the study
  • Requirement of prohibited medications during the study
  • Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions
  • Female subject who is pregnant, breastfeeding, or considering pregnancy during the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
912 participants (actual)

Study arms

  • Placebo comparator
    Placebo / Upadacitinib

    Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16, participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260.

    Drug: Placebo for Upadacitinib · Drug: Upadacitinib

  • Experimental
    Upadacitinib 15 mg QD

    Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks.

    Drug: Upadacitinib

  • Experimental
    Upadacitinib 30 mg QD

    Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks.

    Drug: Upadacitinib

Interventions

  • DrugPlacebo for Upadacitinib

    Tablets taken orally once a day

  • Tablets taken orally once a day

    Also known as: ABT-494, RINVOQ®

06

What researchers measure

Primary outcomes

  1. Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/ neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    Time frame: Baseline and Week 16

  2. Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16

    The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No inflammatory signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification, no oozing or crusting; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification, no oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  2. Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    Time frame: Baseline and Week 16

  3. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 4

  4. Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Week 2

  5. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 1

  6. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11- point scale from 0 (no itch) to 10 (worst imaginable itch). The percentage of participants who had a 4-point or greater improvement from Baseline in Worst Pruritus NRS score at Day 2 was pre-specified as a ranked secondary endpoint for participants in the upadacitinib 30 mg group versus placebo group only.

    Time frame: Baseline and Day 2

  7. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percentage of participants who had a 4-point or greater improvement in Worst Pruritus NRS score from Baseline at Day 3 was pre-specified as a ranked secondary endpoint for participants in the upadacitinib 15 mg group versus placebo group only.

    Time frame: Baseline and Day 3

  8. Main Study: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period

    A flare, characterized as a clinically meaningful worsening in EASI, is defined as an increase in EASI score of ≥ 6.6 points from Baseline during the double-blind treatment period and prior to use of any rescue medication. Flare was assessed in participants with an EASI score of 65.4 or less at Baseline.

    Time frame: From first dose of study drug to Week 16

  9. Main Study: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in Atopic Dermatitis Impact Scale (ADerm-IS) Sleep Domain Score at Week 16

    The ADerm-IS is a 10-item patient reported outcome (PRO) questionnaire designed to assess a variety of impacts that participants experience from their AD. The ADerm-IS sleep domain consists of 3 questions designed to assess the impact of AD on sleep on a daily basis over a 24-hour recall period. The items include difficulty falling asleep, impact on sleep, and waking at night. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The ADerm-IS sleep domain score is the sum of the 3 item scores and ranges from 0 (no impact) to 30 (worst impact). The ADerm-IS sleep domain was analyzed based on weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-IS sleep domain score is 12.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  10. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Atopic Dermatitis Symptom Scale (ADerm-SS) Skin Pain Score at Week 16

    The ADerm-SS is an 11-item PRO questionnaire designed to assess signs and symptoms that patients may experience due to AD using a 24-hour recall period. For the skin pain item participants were asked on a daily basis to indicate how bad their worst skin pain due to AD was in the past 24 hours on an NRS from 0 (no pain) to 10 (worst imaginable pain). The ADerm-SS skin pain score was analyzed using weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-SS skin pain score is 4.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  11. Main Study: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS 7-Item Total Symptom Score (TSS-7) at Week 16

    The ADerm-SS is an 11-item questionnaire designed to assess signs and symptoms that participants may experience due to AD using a 24-hour recall period. The 7-item total symptom score includes 7 symptoms (items 1-7 of the ADerm-SS), each assessed on a NRS from 0 (no symptom) to 10 (worst imaginable). The 7 symptoms included in the score are itch while asleep, itch while awake, skin pain (each assessed daily), skin cracking, skin cracking pain, dry skin, and skin flaking (assessed weekly). The TSS-7 score ranges from 0 to 70, with higher scores indicating worsening symptoms. The minimal clinically important difference for ADerm-SS TSS-7 is 28.

    Time frame: Baseline and Week 16

  12. Main Study: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16

    The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS emotional state sums three items \[Items 8-10\] measuring self-consciousness, embarrassment, and sadness with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The emotional state domain score ranges from 0 to 30, where higher scores represent worst impact. The minimal clinically important difference for ADerm-IS emotional state domain score is 11.

    Time frame: Baseline and Week 16

  13. Main Study: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 16

    The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS Daily Activities sums four items measuring limitations of household, physical, and social activities, and difficulty concentrating with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The daily activities domain score ranges from 0 to 40, where higher scores represent worst impact. The minimal clinically important difference for the ADerm-IS daily activities domain score is 14.

    Time frame: Baseline and Week 16

  14. Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    Time frame: Baseline and Week 16

  15. Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  16. Main Study: Percent Change From Baseline in EASI Score at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 16

  17. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Week 16

    The POEM is a 7-item, validated questionnaire used to assess disease symptoms in both children and adults. Participants respond to 7 questions, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency of occurrence during the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days. Item scores are added to provide a total score ranging from 0 (clear) to 28 (very severe atopic eczema). A change in POEM score of 3.4 points is considered the minimal clinically important difference.

    Time frame: Baseline and Week 16

  18. Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Dermatology Life Quality Index (DLQI) at Week 16

    The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.

    Time frame: Baseline and Week 16

  19. Main Study: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 16

    SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 16

  20. Main Study: Percentage of Participants Achieving a Hospital Anxiety and Depression Scale-Anxiety (HADS-A) Score and Hospital Anxiety and Depression Scale-Depression (HADS-D) Score of < 8 at Week 16

    The HADS is a 14-item questionnaire, with seven items related to anxiety (HADS-A) and seven items related to depression (HADS-D). Each item is scored from 0 to 3; scores for each subscale range from 0 to 21, with higher scores indicating more distress. For each domain, scores 7 or lower are considered normal, 8 to 10 are borderline, and 11 or higher indicate clinical anxiety or depression.

    Time frame: Week 16

  21. Main Study: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16

    The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. The DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.

    Time frame: Week 16

  22. Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Week 16

  23. Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16

    The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification, no oozing or crusting;; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification, no oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.

    Time frame: Baseline and Week 16

  24. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  25. Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Week 16

  26. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 4

  27. Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Week 2

  28. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 1

  29. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: Baseline and Day 2

  30. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: Baseline and Day 3

  31. Adolescents: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period

    A flare, characterized as a clinically meaningful worsening in EASI, is defined as an increase in EASI score of ≥ 6.6 points from Baseline during the double-blind treatment period and prior to use of any rescue medication. Flares were assessed in participants with an EASI score of 65.4 or less at Baseline.

    Time frame: From first dose of study drug to Week 16

  32. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in ADerm-IS Sleep Domain Score at Week 16

    The ADerm-IS is a 10-item patient reported outcome questionnaire designed to assess a variety of impacts that participants experience from their AD. The ADerm-IS sleep domain consists of 3 questions designed to assess the impact of AD on sleep on a daily basis over a 24-hour recall period. The items include difficulty falling asleep, impact on sleep, and waking at night. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The ADerm-IS sleep domain score is the sum of the 3 item scores and ranges from 0 (no impact) to 30 (worst impact). The ADerm-IS sleep domain was analyzed based on weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-IS sleep domain score is 12.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  33. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in ADerm-SS Skin Pain Score at Week 16

    The ADerm-SS is an 11-item PRO questionnaire designed to assess signs and symptoms that patients may experience due to AD using a 24-hour recall period. For the skin pain item participants were asked to indicate on a daily basis how bad their worst skin pain due to AD was in the past 24 hours on an NRS from 0 (no pain) to 10 (worst imaginable pain). The minimal clinically important difference for ADerm-SS skin pain score is 4. The ADerm-SS skin pain score was analyzed based on weekly rolling averages of daily scores.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  34. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS TSS-7 at Week 16

    The ADerm-SS is an 11-item questionnaire designed to assess signs and symptoms that participants may experience due to AD using a 24-hour recall period. The 7-item total symptom score includes 7 symptoms (items 1-7 of the ADerm-SS), each assessed on a NRS from 0 (no symptom) to 10 (worst imaginable). The 7 symptoms included in the score are itch while asleep, itch while awake, skin pain (each assessed daily), skin cracking, skin cracking pain, dry skin, and skin flaking (assessed weekly). The TSS-7 score ranges from 0 to 70, with higher scores indicating worsening symptoms. The minimal clinically important difference for ADerm-SS TSS-7 is 28.

    Time frame: Baseline and Week 16

  35. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16

    The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS emotional state sums three items \[Items 8-10\] measuring self-consciousness, embarrassment, and sadness with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The emotional state domain score ranges from 0 to 30, where higher scores represent worst impact. The minimal clinically important difference for ADerm-IS emotional state domain score is 11.

    Time frame: Baseline and Week 16

  36. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 16

    The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS daily activities sums four items measuring limitations of household, physical, and social activities, and difficulty concentrating with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The daily activities domain score ranges from 0 to 40, where higher scores represent worst impact. The minimal clinically important difference for the ADerm-IS daily activities domain score is 14.

    Time frame: Baseline and Week 16

  37. Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 100 response is defined as a 100% reduction (improvement) from Baseline in EASI score.

    Time frame: Baseline and Week 16

  38. Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16

    Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.

    Time frame: Baseline (last available rolling average before the first dose of study drug) and Week 16

  39. Adolescents: Percent Change From Baseline in EASI Score at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 16

  40. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in POEM Total Score at Week 16

    The POEM is a 7-item, validated questionnaire used to assess disease symptoms in both children and adults. Participants respond to 7 questions, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency of occurrence during the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days. Item scores are added to provide a total score ranging from 0 (clear) to 28 (very severe atopic eczema). A change in POEM score of 3.4 points is considered the minimal clinically important difference.

    Time frame: Baseline and Week 16

  41. Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in DLQI Score at Week 16

    The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.

    Time frame: Baseline and Week 16

  42. Adolescents: Percent Change From Baseline in SCORAD Score at Week 16

    SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A negative change from Baseline indicates improvement.

    Time frame: Baseline and Week 16

  43. Adolescents: Percentage of Participants Achieving HADS-A Score and HADS-D Score of < 8 at Week 16

    The HADS is a 14-item questionnaire, with seven items related to anxiety (HADS-A) and seven items related to depression (HADS-D). Each item is scored from 0 to 3; scores for each subscale range from 0 to 21, with higher scores indicating more distress. For each domain, scores 7 or lower are considered normal, 8 to 10 are borderline, and 11 or higher indicate clinical anxiety or depression.

    Time frame: Week 16

  44. Adolescents: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16

    The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.

    Time frame: Week 16

07

Results

Posted Mar 28, 2022

Participant flow

Participants were enrolled at 165 study sites in 23 countries across Europe, North America, Oceania, and the Asia-Pacific region. The study included a 16-week double-blind treatment period followed by a blinded extension period to Week 260, and a 30-day follow-up visit. 836 adults and adolescents were first enrolled in the Main Study; additional adolescents were enrolled in the Adolescent Substudy to ensure enrollment of 180 adolescents overall. All outcome measures were reported at Week 16.

Double-blind Period
Participant flow — Double-blind Period
MilestoneAdults: Double-blind Period - PlaceboAdults: Double-blind Period - Upadacitinib 15 mg QDAdults: Double-blind Period - Upadacitinib 30 mg QDAdolescents: Double-blind Period - PlaceboAdolescents: Double-blind Period - Upadacitinib 15 mg QDAdolescents: Double-blind Period - Upadacitinib 30 mg QDAdults: Blinded Extension Period - PBO/Upadacitinib 15 mgAdults: Blinded Extension Period - PBO/Upadacitinib 30 mgAdults: Blinded Extension Period - Upadacitinib 15 mgAdults: Blinded Extension Period - Upadacitinib 30 mgAdolescents: Blinded Extension Period - PBO/Upadacitinib 15 mgAdolescents: Blinded Extension Period - PBO/Upadacitinib 30 mgAdolescents: Blinded Extension Period - Upadacitinib 15 mgAdolescents: Blinded Extension Period - Upadacitinib 30 mg
Started24224324760586200000000
Included in week 16 analysis20423323555555900000000
Completed21023323655556000000000
Not completed32101153200000000
Withdrew: Adverse event73102000000000
Withdrew: Withdrawal by subject123721000000000
Withdrew: Lost to follow-up10210000000000
Withdrew: Other124120200000000
Blinded Extension Period
Participant flow — Blinded Extension Period
MilestoneAdults: Double-blind Period - PlaceboAdults: Double-blind Period - Upadacitinib 15 mg QDAdults: Double-blind Period - Upadacitinib 30 mg QDAdolescents: Double-blind Period - PlaceboAdolescents: Double-blind Period - Upadacitinib 15 mg QDAdolescents: Double-blind Period - Upadacitinib 30 mg QDAdults: Blinded Extension Period - PBO/Upadacitinib 15 mgAdults: Blinded Extension Period - PBO/Upadacitinib 30 mgAdults: Blinded Extension Period - Upadacitinib 15 mgAdults: Blinded Extension Period - Upadacitinib 30 mgAdolescents: Blinded Extension Period - PBO/Upadacitinib 15 mgAdolescents: Blinded Extension Period - PBO/Upadacitinib 30 mgAdolescents: Blinded Extension Period - Upadacitinib 15 mgAdolescents: Blinded Extension Period - Upadacitinib 30 mg
Started00000010410423323626295560
Received treatment in the be period00000010410422923526295559
Completed000000505712413910122324
Not completed00000054471099716173236
Withdrew: Adverse event000000141215213415
Withdrew: Withdrawal by subject00000018174140661511
Withdrew: Lost to follow-up000000731191215
Withdrew: Covid-19 infection00000000010000
Withdrew: Other00000015154226651514
Withdrew: 1 subject prematurely discontinued the study during be period after wk 164 with no additional visits00000000000001

Outcome measures

PrimaryMain Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/ neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 1613.3 (9.3 to 17.3)60.1 (54.4 to 65.9)72.9 (67.7 to 78.2)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 59.6 · 95% CI 53.1 to 66.2Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 46.9 · 95% CI 39.9 to 53.9Response Rate Difference = Upadacitinib - Placebo
PrimaryMain Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16

The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No inflammatory signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification, no oozing or crusting; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification, no oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, oozing or crusting may be present; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; Oozing or crusting may be present.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 164.7 (2.2 to 7.2)38.8 (33.0 to 44.5)52.0 (46.1 to 57.9)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 47.4 · 95% CI 41.0 to 53.7Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 34.0 · 95% CI 27.8 to 40.2Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 169.1 (5.7 to 12.5)41.9 (36.0 to 47.7)59.6 (53.9 to 65.4)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 50.4 · 95% CI 43.8 to 57.1Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 32.6 · 95% CI 25.8 to 39.4Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 165.4 (2.7 to 8.1)42.4 (36.6 to 48.2)58.5 (52.7 to 64.2)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 53.1 · 95% CI 46.7 to 59.4Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 36.9 · 95% CI 30.6 to 43.3Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 4
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 43.6 (1.4 to 5.9)48.9 (42.9 to 54.9)60.7 (55.0 to 66.4)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 57.0 · 95% CI 50.9 to 63.0Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 45.2 · 95% CI 38.9 to 51.4Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving an EASI 75 Response at Week 2

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Week 2
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 23.6 (1.4 to 5.8)33.0 (27.4 to 38.5)44.0 (38.2 to 49.8)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 40.4 · 95% CI 34.2 to 46.5Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 29.4 · 95% CI 23.5 to 35.3Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst Pruritus NRS was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 1
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 10.7 (0.0 to 1.7)7.4 (4.3 to 10.5)15.7 (11.5 to 20.0)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 14.9 · 95% CI 10.6 to 19.3Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 6.7 · 95% CI 3.4 to 10.0Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11- point scale from 0 (no itch) to 10 (worst imaginable itch). The percentage of participants who had a 4-point or greater improvement from Baseline in Worst Pruritus NRS score at Day 2 was pre-specified as a ranked secondary endpoint for participants in the upadacitinib 30 mg group versus placebo group only.

Time frame:
Baseline and Day 2
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 20.7 (0.0 to 1.8)7.4 (4.3 to 10.6)7.9 (4.7 to 11.1)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 7.2 · 95% CI 3.8 to 10.5Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percentage of participants who had a 4-point or greater improvement in Worst Pruritus NRS score from Baseline at Day 3 was pre-specified as a ranked secondary endpoint for participants in the upadacitinib 15 mg group versus placebo group only.

Time frame:
Baseline and Day 3
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 33.0 (1.0 to 5.0)11.5 (7.7 to 15.3)17.3 (12.8 to 21.7)
Statistical analysis
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 8.6 · 95% CI 4.3 to 12.9Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period

A flare, characterized as a clinically meaningful worsening in EASI, is defined as an increase in EASI score of ≥ 6.6 points from Baseline during the double-blind treatment period and prior to use of any rescue medication. Flare was assessed in participants with an EASI score of 65.4 or less at Baseline.

Time frame:
From first dose of study drug to Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period24.5 (19.4 to 29.7)2.2 (0.5 to 3.9)1.4 (0.0 to 2.8)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: -23.1 · 95% CI -28.4 to -17.8Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: -22.4 · 95% CI -27.8 to -16.9Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in Atopic Dermatitis Impact Scale (ADerm-IS) Sleep Domain Score at Week 16

The ADerm-IS is a 10-item patient reported outcome (PRO) questionnaire designed to assess a variety of impacts that participants experience from their AD. The ADerm-IS sleep domain consists of 3 questions designed to assess the impact of AD on sleep on a daily basis over a 24-hour recall period. The items include difficulty falling asleep, impact on sleep, and waking at night. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The ADerm-IS sleep domain score is the sum of the 3 item scores and ranges from 0 (no impact) to 30 (worst impact). The ADerm-IS sleep domain was analyzed based on weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-IS sleep domain score is 12.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in Atopic Dermatitis Impact Scale (ADerm-IS) Sleep Domain Score at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in Atopic Dermatitis Impact Scale (ADerm-IS) Sleep Domain Score at Week 1612.4 (8.2 to 16.7)50.2 (43.6 to 56.9)62.3 (56.0 to 68.6)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 49.8 · 95% CI 42.2 to 57.3Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 37.9 · 95% CI 30.1 to 45.8Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Atopic Dermatitis Symptom Scale (ADerm-SS) Skin Pain Score at Week 16

The ADerm-SS is an 11-item PRO questionnaire designed to assess signs and symptoms that patients may experience due to AD using a 24-hour recall period. For the skin pain item participants were asked on a daily basis to indicate how bad their worst skin pain due to AD was in the past 24 hours on an NRS from 0 (no pain) to 10 (worst imaginable pain). The ADerm-SS skin pain score was analyzed using weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-SS skin pain score is 4.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Atopic Dermatitis Symptom Scale (ADerm-SS) Skin Pain Score at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Atopic Dermatitis Symptom Scale (ADerm-SS) Skin Pain Score at Week 1613.4 (9.1 to 17.6)49.4 (43.0 to 55.7)65.1 (59.1 to 71.2)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 51.8 · 95% CI 44.4 to 59.1Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 35.9 · 95% CI 28.2 to 43.5Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS 7-Item Total Symptom Score (TSS-7) at Week 16

The ADerm-SS is an 11-item questionnaire designed to assess signs and symptoms that participants may experience due to AD using a 24-hour recall period. The 7-item total symptom score includes 7 symptoms (items 1-7 of the ADerm-SS), each assessed on a NRS from 0 (no symptom) to 10 (worst imaginable). The 7 symptoms included in the score are itch while asleep, itch while awake, skin pain (each assessed daily), skin cracking, skin cracking pain, dry skin, and skin flaking (assessed weekly). The TSS-7 score ranges from 0 to 70, with higher scores indicating worsening symptoms. The minimal clinically important difference for ADerm-SS TSS-7 is 28.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS 7-Item Total Symptom Score (TSS-7) at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS 7-Item Total Symptom Score (TSS-7) at Week 1612.7 (8.5 to 16.9)53.0 (46.6 to 59.5)66.2 (60.2 to 72.3)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 53.3 · 95% CI 46.0 to 60.6Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 40.3 · 95% CI 32.7 to 48.0Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16

The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS emotional state sums three items \[Items 8-10\] measuring self-consciousness, embarrassment, and sadness with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The emotional state domain score ranges from 0 to 30, where higher scores represent worst impact. The minimal clinically important difference for ADerm-IS emotional state domain score is 11.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 1616.7 (11.9 to 21.4)57.0 (50.6 to 63.4)71.5 (65.6 to 77.4)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 54.8 · 95% CI 47.2 to 62.3Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 40.3 · 95% CI 32.3 to 48.3Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 16

The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS Daily Activities sums four items measuring limitations of household, physical, and social activities, and difficulty concentrating with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The daily activities domain score ranges from 0 to 40, where higher scores represent worst impact. The minimal clinically important difference for the ADerm-IS daily activities domain score is 14.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 1618.9 (13.8 to 24.0)57.0 (50.3 to 63.7)69.5 (63.5 to 75.5)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 50.6 · 95% CI 42.8 to 58.5Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 37.9 · 95% CI 29.5 to 46.3Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 160.7 (0.0 to 1.7)14.1 (10.0 to 18.2)18.8 (14.2 to 23.4)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.0001 · Adjusted response rate difference: 18.1 · 95% CI 13.5 to 22.7Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 13.4 · 95% CI 9.2 to 17.6Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Least squares mean · percent change
Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16
percent changePlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16-17.04 (-22.39 to -11.69)-51.20 (-55.80 to -46.61)-66.49 (-71.03 to -61.96)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Least squares (ls) mean difference: -49.45 · 95% CI -56.05 to -42.84Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -34.16 · 95% CI -40.81 to -27.51Difference = Upadacitinib - Placebo
SecondaryMain Study: Percent Change From Baseline in EASI Score at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · percent change
Main Study: Percent Change From Baseline in EASI Score at Week 16
percent changePlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percent Change From Baseline in EASI Score at Week 16-34.51 (-39.60 to -29.42)-74.13 (-78.45 to -69.82)-84.65 (-88.93 to -80.37)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -50.14 · 95% CI -56.28 to -44.00Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -39.62 · 95% CI -45.79 to -33.46Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Week 16

The POEM is a 7-item, validated questionnaire used to assess disease symptoms in both children and adults. Participants respond to 7 questions, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency of occurrence during the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days. Item scores are added to provide a total score ranging from 0 (clear) to 28 (very severe atopic eczema). A change in POEM score of 3.4 points is considered the minimal clinically important difference.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Week 1628.7 (23.3 to 34.1)70.9 (65.5 to 76.3)83.5 (79.1 to 88.0)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 54.7 · 95% CI 47.7 to 61.7Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 42.1 · 95% CI 34.5 to 49.8Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Dermatology Life Quality Index (DLQI) at Week 16

The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Dermatology Life Quality Index (DLQI) at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Dermatology Life Quality Index (DLQI) at Week 1628.4 (22.8 to 34.0)71.7 (66.1 to 77.3)77.6 (72.5 to 82.8)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 49.0 · 95% CI 41.4 to 56.5Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = 0.002 · Adjusted response rate difference: 42.8 · 95% CI 35.0 to 50.6Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 16

SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · percent change
Main Study: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 16
percent changePlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 16-28.43 (-33.34 to -23.52)-57.90 (-61.84 to -53.97)-68.44 (-72.44 to -64.44)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -40.01 · 95% CI -45.80 to -34.22Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -29.47 · 95% CI -35.24 to -23.69Mixed-effect model repeat measurement with Baseline, treatment, visit, treatment by visit interaction, Baseline vIGA-AD category and age in the model.
SecondaryMain Study: Percentage of Participants Achieving a Hospital Anxiety and Depression Scale-Anxiety (HADS-A) Score and Hospital Anxiety and Depression Scale-Depression (HADS-D) Score of < 8 at Week 16

The HADS is a 14-item questionnaire, with seven items related to anxiety (HADS-A) and seven items related to depression (HADS-D). Each item is scored from 0 to 3; scores for each subscale range from 0 to 21, with higher scores indicating more distress. For each domain, scores 7 or lower are considered normal, 8 to 10 are borderline, and 11 or higher indicate clinical anxiety or depression.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a Hospital Anxiety and Depression Scale-Anxiety (HADS-A) Score and Hospital Anxiety and Depression Scale-Depression (HADS-D) Score of < 8 at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a Hospital Anxiety and Depression Scale-Anxiety (HADS-A) Score and Hospital Anxiety and Depression Scale-Depression (HADS-D) Score of < 8 at Week 1611.4 (6.2 to 16.7)46.0 (37.6 to 54.3)56.1 (48.1 to 64.2)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 44.5 · 95% CI 35.0 to 54.1Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 34.4 · 95% CI 24.7 to 44.2Response Rate Difference = Upadacitinib - Placebo
SecondaryMain Study: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16

The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. The DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Main Study: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16
percentage of participantsPlaceboUpadacitinib 15 mg QDUpadacitinib 30 mg QD
Main Study: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 164.7 (2.1 to 7.2)23.8 (18.6 to 29.1)37.9 (32.0 to 43.9)
Statistical analysis
  • Placebo vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 33.3 · 95% CI 26.9 to 39.8Response Rate Difference = Upadacitinib - Placebo
  • Placebo vs Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 19.1 · 95% CI 13.3 to 24.9Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 1613.3 (4.7 to 21.9)69.0 (57.1 to 80.9)73.4 (62.3 to 84.6)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 59.9 · 95% CI 45.9 to 73.8Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 55.8 · 95% CI 41.1 to 70.4Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16

The vIGA-AD is a validated assessment instrument to rate the severity of atopic dermatitis globally, based on the following scale: * 0 - Clear: No signs of AD; * 1 - Almost clear: Barely perceptible erythema, induration/papulation and/or lichenification, no oozing or crusting;; * 2 - Mild: Slight but definite erythema, induration/papulation and/or minimal lichenification, no oozing or crusting; * 3 - Moderate: Clearly perceptible erythema, induration/papulation and/or lichenification, possible oozing or crusting; * 4 - Severe: Marked erythema, induration/papulation and/or lichenification; possible oozing or crusting.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 165.0 (0.0 to 10.5)44.8 (32.0 to 57.6)59.4 (47.0 to 71.8)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 53.9 · 95% CI 40.6 to 67.3Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 39.4 · 95% CI 25.7 to 53.1Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 163.4 (0.0 to 8.0)38.2 (25.3 to 51.0)56.7 (44.1 to 69.2)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 53.1 · 95% CI 40.0 to 66.1Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 35.0 · 95% CI 21.8 to 48.2Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 90 response is defined as at least a 90% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 161.7 (0.0 to 4.9)48.3 (35.4 to 61.1)62.0 (49.8 to 74.3)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 60.2 · 95% CI 47.5 to 72.9Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 46.7 · 95% CI 33.4 to 59.9Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 4
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 4
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 43.4 (0.0 to 8.0)38.2 (25.3 to 51.0)50.0 (37.3 to 62.7)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 46.4 · 95% CI 33.2 to 59.6Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 34.9 · 95% CI 21.4 to 48.4Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 75 response is defined as at least a 75% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Week 2
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 26.7 (0.4 to 13.0)37.9 (25.4 to 50.4)53.2 (40.8 to 65.6)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 46.2 · 95% CI 32.4 to 60.0Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 31.3 · 95% CI 17.3 to 45.3Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst pruritus NRS was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 1
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 10.0 (NA to NA)12.7 (3.9 to 21.5)5.0 (0.0 to 10.5)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = 0.075 · Adjusted response rate difference: 5.0 · 95% CI -0.5 to 10.6Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = 0.005 · Adjusted response rate difference: 12.7 · 95% CI 3.9 to 21.5Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

Time frame:
Baseline and Day 2
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 2
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 20.0 (NA to NA)8.9 (1.5 to 16.4)3.2 (0.0 to 7.6)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = 0.151 · Adjusted response rate difference: 3.2 · 95% CI -1.2 to 7.6Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

Time frame:
Baseline and Day 3
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 3
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Day 31.7 (0.0 to 5.0)14.3 (5.1 to 23.5)9.7 (2.3 to 17.0)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = 0.008 · Adjusted response rate difference: 12.9 · 95% CI 3.4 to 22.3Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period

A flare, characterized as a clinically meaningful worsening in EASI, is defined as an increase in EASI score of ≥ 6.6 points from Baseline during the double-blind treatment period and prior to use of any rescue medication. Flares were assessed in participants with an EASI score of 65.4 or less at Baseline.

Time frame:
From first dose of study drug to Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period20.0 (9.9 to 30.1)1.7 (0.0 to 5.1)1.6 (0.0 to 4.8)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: -18.0 · 95% CI -28.0 to -8.0Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted response rate difference: -17.9 · 95% CI -28.1 to -7.7Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in ADerm-IS Sleep Domain Score at Week 16

The ADerm-IS is a 10-item patient reported outcome questionnaire designed to assess a variety of impacts that participants experience from their AD. The ADerm-IS sleep domain consists of 3 questions designed to assess the impact of AD on sleep on a daily basis over a 24-hour recall period. The items include difficulty falling asleep, impact on sleep, and waking at night. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The ADerm-IS sleep domain score is the sum of the 3 item scores and ranges from 0 (no impact) to 30 (worst impact). The ADerm-IS sleep domain was analyzed based on weekly rolling averages of daily scores. The minimal clinically important difference for ADerm-IS sleep domain score is 12.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in ADerm-IS Sleep Domain Score at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 12 Points From Baseline in ADerm-IS Sleep Domain Score at Week 169.5 (0.6 to 18.4)37.5 (22.5 to 52.5)61.4 (47.0 to 75.8)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 51.5 · 95% CI 34.8 to 68.3Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = 0.001 · Adjusted response rate difference: 29.2 · 95% CI 11.8 to 46.6Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in ADerm-SS Skin Pain Score at Week 16

The ADerm-SS is an 11-item PRO questionnaire designed to assess signs and symptoms that patients may experience due to AD using a 24-hour recall period. For the skin pain item participants were asked to indicate on a daily basis how bad their worst skin pain due to AD was in the past 24 hours on an NRS from 0 (no pain) to 10 (worst imaginable pain). The minimal clinically important difference for ADerm-SS skin pain score is 4. The ADerm-SS skin pain score was analyzed based on weekly rolling averages of daily scores.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in ADerm-SS Skin Pain Score at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in ADerm-SS Skin Pain Score at Week 167.5 (0.4 to 14.7)39.6 (25.7 to 53.4)60.8 (47.4 to 74.2)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 53.2 · 95% CI 38.4 to 68.0Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 31.8 · 95% CI 16.5 to 47.1Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS TSS-7 at Week 16

The ADerm-SS is an 11-item questionnaire designed to assess signs and symptoms that participants may experience due to AD using a 24-hour recall period. The 7-item total symptom score includes 7 symptoms (items 1-7 of the ADerm-SS), each assessed on a NRS from 0 (no symptom) to 10 (worst imaginable). The 7 symptoms included in the score are itch while asleep, itch while awake, skin pain (each assessed daily), skin cracking, skin cracking pain, dry skin, and skin flaking (assessed weekly). The TSS-7 score ranges from 0 to 70, with higher scores indicating worsening symptoms. The minimal clinically important difference for ADerm-SS TSS-7 is 28.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS TSS-7 at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 28 Points From Baseline in ADerm-SS TSS-7 at Week 1610.9 (2.7 to 19.1)47.9 (33.8 to 62.0)60.0 (47.1 to 72.9)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 48.9 · 95% CI 33.8 to 64.1Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 37.3 · 95% CI 21.1 to 53.6Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16

The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS emotional state sums three items \[Items 8-10\] measuring self-consciousness, embarrassment, and sadness with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The emotional state domain score ranges from 0 to 30, where higher scores represent worst impact. The minimal clinically important difference for ADerm-IS emotional state domain score is 11.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 1618.0 (7.4 to 28.6)60.0 (45.7 to 74.3)72.0 (59.6 to 84.4)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 53.8 · 95% CI 37.4 to 70.2Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 42.0 · 95% CI 24.3 to 59.7Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 16

The ADerm-IS is a 10-item PRO questionnaire designed to assess a variety of impacts that participants experience from their AD. ADerm-IS daily activities sums four items measuring limitations of household, physical, and social activities, and difficulty concentrating with a 7-day recall. Each question is scored on an 11-point NRS from 0 (no impact) to 10 (extreme impact). The daily activities domain score ranges from 0 to 40, where higher scores represent worst impact. The minimal clinically important difference for the ADerm-IS daily activities domain score is 14.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 1622.4 (10.8 to 34.1)52.5 (37.0 to 68.0)68.0 (55.1 to 80.9)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 45.3 · 95% CI 28.0 to 62.7Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = 0.002 · Adjusted response rate difference: 29.8 · 95% CI 10.7 to 48.8Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease. An EASI 100 response is defined as a 100% reduction (improvement) from Baseline in EASI score.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 161.7 (0.0 to 4.9)15.5 (6.2 to 24.8)19.4 (9.5 to 29.2)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 17.1 · 95% CI 7.5 to 26.7Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = 0.006 · Adjusted response rate difference: 13.7 · 95% CI 3.9 to 23.5Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16

Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on a daily basis using an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). Worst Pruritus NRS was analyzed based on weekly rolling averages of daily scores. A negative change from Baseline indicates improvement.

Time frame:
Baseline (last available rolling average before the first dose of study drug) and Week 16
Reported as:
Least squares mean · percent change
Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16
percent changeAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16-11.02 (-22.14 to 0.10)-47.56 (-57.00 to -38.13)-66.95 (-76.07 to -57.84)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -55.93 · 95% CI -70.32 to -41.55Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -36.54 · 95% CI -51.12 to -21.96Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percent Change From Baseline in EASI Score at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1)\] moderate \[2\], or severe \[3\]) for Redness (erythema, inflammation), Thickness (induration, papulation, swelling - acute eczema), Scratching (excoriation), and Lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease; a negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · percent change
Adolescents: Percent Change From Baseline in EASI Score at Week 16
percent changeAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percent Change From Baseline in EASI Score at Week 16-42.19 (-52.06 to -32.33)-77.85 (-85.95 to -69.74)-84.81 (-92.84 to -76.78)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -42.62 · 95% CI -55.34 to -29.90Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -35.66 · 95% CI -48.41 to -22.90Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in POEM Total Score at Week 16

The POEM is a 7-item, validated questionnaire used to assess disease symptoms in both children and adults. Participants respond to 7 questions, including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping, each scored on a 5-point scale based on frequency of occurrence during the previous week: 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days. Item scores are added to provide a total score ranging from 0 (clear) to 28 (very severe atopic eczema). A change in POEM score of 3.4 points is considered the minimal clinically important difference.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in POEM Total Score at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in POEM Total Score at Week 1628.1 (16.4 to 39.7)66.1 (53.7 to 78.5)80.7 (70.5 to 90.9)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 52.5 · 95% CI 36.9 to 68.1Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 38.1 · 95% CI 21.2 to 54.9Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in DLQI Score at Week 16

The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in DLQI Score at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in DLQI Score at Week 1619.2 (4.1 to 34.4)68.2 (48.7 to 87.6)73.3 (57.5 to 89.2)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 55.9 · 95% CI 35.5 to 76.3Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 49.6 · 95% CI 26.3 to 72.9Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percent Change From Baseline in SCORAD Score at Week 16

SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). The extent is assessed using the rule of 9 to calculate the affected area (A) as a percentage of the whole body (0-100%). The intensity part of the SCORAD (B) consists of 6 items: erythema, oedema/papulation, excoriations, lichenification, oozing/crusts and dryness, each graded on a scale from 0 (none) to 3 (severe), for a total score of 0 to 18. Subjective items (C) include daily pruritus and sleeplessness, each scored on a visual analogue scale (VAS) from 0 to 10 (total score 0-20). SCORAD is calculated as A/5 + 7B/2 + C, and ranges from 0 to 103 (worst). A negative change from Baseline indicates improvement.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · percent change
Adolescents: Percent Change From Baseline in SCORAD Score at Week 16
percent changeAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percent Change From Baseline in SCORAD Score at Week 16-27.91 (-37.98 to -17.83)-57.89 (-65.49 to -50.28)-72.81 (-80.77 to -64.85)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -44.90 · 95% CI -57.74 to -32.06Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 · Ls mean difference: -29.98 · 95% CI -42.60 to -17.36Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving HADS-A Score and HADS-D Score of < 8 at Week 16

The HADS is a 14-item questionnaire, with seven items related to anxiety (HADS-A) and seven items related to depression (HADS-D). Each item is scored from 0 to 3; scores for each subscale range from 0 to 21, with higher scores indicating more distress. For each domain, scores 7 or lower are considered normal, 8 to 10 are borderline, and 11 or higher indicate clinical anxiety or depression.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving HADS-A Score and HADS-D Score of < 8 at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving HADS-A Score and HADS-D Score of < 8 at Week 1616.0 (1.6 to 30.4)37.5 (18.1 to 56.9)43.8 (26.6 to 60.9)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = 0.016 · Adjusted response rate difference: 27.8 · 95% CI 5.2 to 50.4Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = 0.062 · Adjusted response rate difference: 22.3 · 95% CI -1.1 to 45.7Response Rate Difference = Upadacitinib - Placebo
SecondaryAdolescents: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16

The DLQI is a 10-item validated questionnaire used to assess the impact of AD disease symptoms and treatment on quality of life (QoL). It consists of 10 questions evaluating impact of skin diseases on different aspects of a participant's QoL over the prior week, including symptoms and feelings, daily activities, leisure, work or school, personal relationships, and the side effects of treatment. Each item is scored on a 4-point scale (0 = not at all/not relevant; 1 = a little; 2 = a lot; and 3 = very much). Item scores are added to provide a total score, ranging from 0 to 30, with higher scores indicating greater impairment of QoL. A score of 0 or 1 means that the disease has no effect at all. the DLQI was administered to participants who were ≥ 16 (16 to 75) years old at the time of the Screening visit.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Adolescents: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16
percentage of participantsAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QD
Adolescents: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 167.7 (0.0 to 17.9)13.6 (0.0 to 28.0)46.9 (29.6 to 64.2)
Statistical analysis
  • Adolescents: Placebo vs Adolescents: Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 · Adjusted response rate difference: 38.9 · 95% CI 18.4 to 59.4Response Rate Difference = Upadacitinib - Placebo
  • Adolescents: Placebo vs Adolescents: Upadacitinib 15 mg QD · Cochran-Mantel-Haenszel · p = 0.510 · Adjusted response rate difference: 5.9 · 95% CI -11.7 to 23.6Response Rate Difference = Upadacitinib - Placebo

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from enrollment to the end of the study. The median time followed ranged from 132 days to 137 days for the double-blind period and from 1234 days to 1713 days for the blinded extension period.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adults: Double-blind Period - Placebo0/242 (0%)7/242 (2.9%)93/242 (38.4%)
Adults: Double-blind Period - Upadacitinib 15 mg QD0/243 (0%)3/243 (1.2%)117/243 (48.1%)
Adults: Double-blind Period - Upadacitinib 30 mg QD0/247 (0%)7/247 (2.8%)126/247 (51%)
Adolescents: Double-blind Period - Placebo0/60 (0%)3/60 (5%)19/60 (31.7%)
Adolescents: Double-blind Period - Upadacitinib 15 mg QD0/58 (0%)2/58 (3.4%)26/58 (44.8%)
Adolescents: Double-blind Period - Upadacitinib 30 mg QD0/62 (0%)0/62 (0%)33/62 (53.2%)
Adults: Blinded Extension Period - Upadacitinib 15 mg1/229 (0.4%)38/229 (16.6%)180/229 (78.6%)
Adults: Blinded Extension Period - Upadacitinib 30 mg1/235 (0.4%)41/235 (17.4%)186/235 (79.1%)
Adolescents: Blinded Extension Period - Upadacitinib 15 mg0/55 (0%)6/55 (10.9%)38/55 (69.1%)
Adolescents: Blinded Extension Period - Upadacitinib 30 mg0/59 (0%)10/59 (16.9%)46/59 (78%)
Adults: Blinded Extension Period - PBO/Upadacitinib 15 mg1/104 (1%)11/104 (10.6%)78/104 (75%)
Adults: Blinded Extension Period - PBO/Upadacitinib 30 mg0/104 (0%)18/104 (17.3%)80/104 (76.9%)
Adolescents: Blinded Extension Period - PBO/Upadacitinib 15 mg0/26 (0%)4/26 (15.4%)19/26 (73.1%)
Adolescents: Blinded Extension Period - PBO/Upadacitinib 30 mg0/29 (0%)4/29 (13.8%)23/29 (79.3%)
Most frequent serious events
Showing 10 of 148
Most frequent serious events
EventAdults: Double-blind Period - PlaceboAdults: Double-blind Period - Upadacitinib 15 mg QDAdults: Double-blind Period - Upadacitinib 30 mg QDAdolescents: Double-blind Period - PlaceboAdolescents: Double-blind Period - Upadacitinib 15 mg QDAdolescents: Double-blind Period - Upadacitinib 30 mg QDAdults: Blinded Extension Period - Upadacitinib 15 mgAdults: Blinded Extension Period - Upadacitinib 30 mgAdolescents: Blinded Extension Period - Upadacitinib 15 mgAdolescents: Blinded Extension Period - Upadacitinib 30 mgAdults: Blinded Extension Period - PBO/Upadacitinib 15 mgAdults: Blinded Extension Period - PBO/Upadacitinib 30 mgAdolescents: Blinded Extension Period - PBO/Upadacitinib 15 mgAdolescents: Blinded Extension Period - PBO/Upadacitinib 30 mg
ABORTION INDUCEDSurgical and medical procedures0/2420/2430/2470/600/580/622/2291/2350/553/590/1040/1040/260/29
COLITIS ULCERATIVEGastrointestinal disorders0/2420/2430/2470/600/580/620/2290/2350/550/590/1040/1041/260/29
DERMATITIS INFECTEDInfections and infestations0/2420/2430/2470/600/580/620/2290/2350/550/590/1040/1041/260/29
ECZEMA INFECTEDInfections and infestations0/2420/2430/2470/600/580/620/2290/2351/550/590/1040/1041/260/29
STAPHYLOCOCCAL SKIN INFECTIONInfections and infestations0/2420/2430/2470/600/580/620/2290/2350/550/590/1040/1041/260/29
ADJUSTMENT DISORDERPsychiatric disorders0/2420/2430/2470/600/580/620/2290/2350/550/590/1040/1041/260/29
SUICIDE ATTEMPTPsychiatric disorders1/2420/2431/2470/601/580/620/2290/2351/550/590/1040/1041/261/29
ASTHMARespiratory, thoracic and mediastinal disorders0/2420/2430/2470/600/580/621/2291/2350/550/591/1041/1041/260/29
ECZEMASkin and subcutaneous tissue disorders1/2420/2430/2470/600/580/621/2290/2350/550/590/1041/1041/260/29
CATARACTEye disorders0/2420/2430/2470/600/580/620/2290/2350/550/590/1040/1040/261/29
Most frequent other events
Showing 10 of 51
Most frequent other events
EventAdults: Double-blind Period - PlaceboAdults: Double-blind Period - Upadacitinib 15 mg QDAdults: Double-blind Period - Upadacitinib 30 mg QDAdolescents: Double-blind Period - PlaceboAdolescents: Double-blind Period - Upadacitinib 15 mg QDAdolescents: Double-blind Period - Upadacitinib 30 mg QDAdults: Blinded Extension Period - Upadacitinib 15 mgAdults: Blinded Extension Period - Upadacitinib 30 mgAdolescents: Blinded Extension Period - Upadacitinib 15 mgAdolescents: Blinded Extension Period - Upadacitinib 30 mgAdults: Blinded Extension Period - PBO/Upadacitinib 15 mgAdults: Blinded Extension Period - PBO/Upadacitinib 30 mgAdolescents: Blinded Extension Period - PBO/Upadacitinib 15 mgAdolescents: Blinded Extension Period - PBO/Upadacitinib 30 mg
COVID-19Infections and infestations0/2420/2430/2470/600/583/6273/22970/23515/5519/5933/10441/1046/2612/29
ACNESkin and subcutaneous tissue disorders5/24231/24337/2472/606/589/6225/22924/23510/557/5920/10426/1045/2610/29
DERMATITIS ATOPICSkin and subcutaneous tissue disorders18/2429/2433/2478/601/581/6241/22935/2357/557/5912/10416/1045/267/29
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations12/24214/24315/2471/606/583/6233/22920/23512/554/5910/10410/1043/263/29
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations6/2428/24312/2471/603/586/6228/22943/2359/5511/5918/10413/1042/265/29
PYREXIAGeneral disorders3/2424/2436/2470/602/582/6217/2297/2356/557/590/1048/1043/265/29
HEADACHENervous system disorders12/24217/24316/2472/603/585/6211/22913/2356/554/599/1046/1041/265/29
HERPES ZOSTERInfections and infestations2/2426/2431/2470/600/580/6217/22933/2354/553/598/1047/1040/260/29
NASOPHARYNGITISInfections and infestations11/24215/24320/2472/602/580/6220/22931/2355/556/5912/10411/1041/261/29
EAR INFECTIONInfections and infestations0/2421/2430/2470/600/580/623/2294/2351/550/592/1043/1043/260/29

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)Adults: PlaceboAdults: Upadacitinib 15 mg QDAdults: Upadacitinib 30 mg QDAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QDTotal
Mean36.0 ± 14.0835.7 ± 15.1536.7 ± 15.3615.5 ± 1.6715.2 ± 1.7915.8 ± 1.7032.1 ± 15.66
Age, Customized
Age, Customized(Participants)Adults: PlaceboAdults: Upadacitinib 15 mg QDAdults: Upadacitinib 30 mg QDAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QDTotal
12 - 14 years00018231556
15 - 17 years000423547124
18 - < 40 years161165161000487
40 - < 65 years706367000200
≥ 65 years11151900045
Sex: Female, Male
Sex: Female, Male(Participants)Adults: PlaceboAdults: Upadacitinib 15 mg QDAdults: Upadacitinib 30 mg QDAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QDTotal
Female104102103353826408
Male138141144252036504
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Adults: PlaceboAdults: Upadacitinib 15 mg QDAdults: Upadacitinib 30 mg QDAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QDTotal
Hispanic or Latino25181710121193
Not Hispanic or Latino217225230504651819
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Adults: PlaceboAdults: Upadacitinib 15 mg QDAdults: Upadacitinib 30 mg QDAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QDTotal
American Indian or Alaska Native54102113
Asian5262556512192
Native Hawaiian or Other Pacific Islander1001204
Black or African American15161775363
White165160172454246630
More than one race41212010
Unknown or Not Reported0000000
Study Enrollment
Study Enrollment(Participants)Adults: PlaceboAdults: Upadacitinib 15 mg QDAdults: Upadacitinib 30 mg QDAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QDTotal
Main Study242243247363335836
Adolescent Substudy00024252776
Geographic Region
Geographic Region(Participants)Adults: PlaceboAdults: Upadacitinib 15 mg QDAdults: Upadacitinib 30 mg QDAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QDTotal
US/Puerto Rico/Canada959599252427365
Other147148148353435547
vIGA-AD
vIGA-AD(Participants)Adults: PlaceboAdults: Upadacitinib 15 mg QDAdults: Upadacitinib 30 mg QDAdolescents: PlaceboAdolescents: Upadacitinib 15 mg QDAdolescents: Upadacitinib 30 mg QDTotal
3 (Moderate)110111111262729414
4 (Severe)132132136343133498

2 further baseline measures are reported on the registry.

08

Study locations

196 sites
  • Total Skin and Beauty Derm Ctr /ID# 205129
    Birmingham, Alabama 35205, United States
  • Medical Dermatology Specialist /ID# 205516
    Phoenix, Arizona 85006-2722, United States
  • Arizona Research Center, Inc. /ID# 205795
    Phoenix, Arizona 85053-4061, United States
  • The Dermatology Clinic of Arkansas /ID# 218749
    Bryant, Arkansas 72022-7514, United States
  • Arkansas Research Trials /ID# 218469
    North Little Rock, Arkansas 72117, United States
  • Encino Research Center /ID# 207472
    Encino, California 91436, United States
  • University of California Irvine /ID# 205136
    Irvine, California 92697-1385, United States
  • Ark Clinical Research /ID# 218193
    Long Beach, California 90806-2325, United States
  • Keck School of Medicine of USC /ID# 206971
    Los Angeles, California 90033, United States
  • Wallace Medical Group /ID# 205701
    Los Angeles, California 90056, United States
  • Child Hosp of Orange County,CA /ID# 205735
    Orange, California 92868, United States
  • Palmtree Clinical Research Inc. /Id# 206184
    Palm Springs, California 92262, United States
  • Rady Children's Hospital San Diego /ID# 208244
    San Diego, California 92123, United States
  • Southern California Derma. Inc /ID# 205734
    Santa Ana, California 92701, United States
  • Innovative Clinical Research - Lafayette /ID# 208400
    Lafayette, Colorado 80026, United States
  • New England Research Associates, LLC /ID# 206896
    Bridgeport, Connecticut 06606-1827, United States
  • Ideal Clinical Research Inc. /ID# 209880
    Aventura, Florida 33180, United States
  • Skin Care Research, LLC /ID# 207099
    Boca Raton, Florida 33486-2269, United States
  • Midflorida Clinical Research, Inc. /ID# 213700
    Brandon, Florida 33511-5335, United States
  • Clinical Research of West Florida, Inc /ID# 206146
    Clearwater, Florida 33765, United States
  • Revival Research /ID# 208383
    Doral, Florida 33122-1902, United States
  • Universal Axon Clinical Research /ID# 213703
    Doral, Florida 33166, United States
  • Lakes Research, LLC /ID# 209156
    Miami, Florida 33014, United States
  • Miami Dade Medical Research Institute /ID# 209413
    Miami, Florida 33176, United States
  • Savin Medical Group, LLC /ID# 206902
    Miami Lakes, Florida 33014-2490, United States
  • Floridian Clinical Research /ID# 207433
    Miami Lakes, Florida 33016-1842, United States
  • Advanced Research for Health Improvement /ID# 217987
    Naples, Florida 34102-5430, United States
  • Advanced Research for Health Improvement /ID# 218003
    Naples, Florida 34102-5430, United States
  • Complete Health Research /ID# 213459
    Ormond Beach, Florida 32174-6302, United States
  • Precision Clinical Research /ID# 207364
    Sunrise, Florida 33351-7311, United States
  • Clinical Research Trials of Florida, Inc. /ID# 206840
    Tampa, Florida 33607, United States
  • ForCare Clinical Research /ID# 205120
    Tampa, Florida 33613-1244, United States
  • Georgia Pollens Clinical Research Centers, Inc /ID# 218567
    Albany, Georgia 31707-1282, United States
  • Marietta Dermatology Clinical Research /ID# 210317
    Marietta, Georgia 30060-1047, United States
  • Agile Clinical Research Trials /ID# 218080
    Sandy Springs, Georgia 30342, United States
  • Treasure Valley Medical Research /ID# 210298
    Boise, Idaho 83706, United States
  • Great Lakes Clinical Trials /ID# 205830
    Chicago, Illinois 60640, United States
  • Ashira Dermatology /ID# 205512
    Gurnee, Illinois 60031-3393, United States
  • Clinical Investigation Specialists, Inc. /ID# 206898
    Gurnee, Illinois 60031, United States
  • Northshore University Health System Dermatology Clinical Trials Unit /ID# 205135
    Skokie, Illinois 60077, United States
  • Raga Clinical Studies, LLC. /ID# 206749
    Crown Point, Indiana 46307, United States
  • Hutchinson Clinic /ID# 205970
    Hutchinson, Kansas 67502-1131, United States
  • Continental Clinical Solutions /ID# 210327
    Towson, Maryland 21204, United States
  • Beacon Clinical Research, LLC /ID# 206894
    Quincy, Massachusetts 02169, United States
  • David Fivenson, MD, PLC /ID# 206903
    Ann Arbor, Michigan 48103, United States
  • University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 206895
    Ann Arbor, Michigan 48109, United States
  • Allergy, Asthma & Immunology Associates, PC /ID# 218169
    Lincoln, Nebraska 68505-2343, United States
  • Skin Specialists, PC /ID# 205515
    Omaha, Nebraska 68144, United States
  • Duplicate_Summit Medical Group /ID# 213863
    Clifton, New Jersey 07012-1647, United States
  • Skin Laser and Surgery Specialists of NY and NJ /ID# 206754
    Hackensack, New Jersey 07601-1997, United States
  • Care Access Research /ID# 218476
    Hoboken, New Jersey 07030-2757, United States
  • University of New Mexico School of Medicine /ID# 206756
    Albuquerque, New Mexico 87131-0001, United States
  • Fordham Dermatology /ID# 218508
    The Bronx, New York 10458-5046, United States
  • PMG Research of Wilmington LLC /ID# 205968
    Wilmington, North Carolina 28401, United States
  • University Hospitals Case Medical Center /ID# 206639
    Cleveland, Ohio 44106, United States
  • Awasty Research Network, LLC /ID# 206748
    Marion, Ohio 43302-6225, United States
  • Southside Dermatology /ID# 214451
    Tulsa, Oklahoma 74132, United States
  • Vital Prospects Clinical Research Institute, PC /ID# 205824
    Tulsa, Oklahoma 74136-7049, United States
  • Cyn3rgy Research /ID# 218064
    Gresham, Oregon 97030-8316, United States
  • Velocity Clinical Research Hallandale Beach /ID# 207544
    Medford, Oregon 97504, United States
  • Clinical Research Solutions, LLC /ID# 218416
    Jackson, Tennessee 38305-2163, United States
  • Stones River Dermatology /ID# 205178
    Murfreesboro, Tennessee 37129-3194, United States
  • Metroplex Dermatology /ID# 213307
    Arlington, Texas 76014-3105, United States
  • Bellaire Dermatology /ID# 205470
    Bellaire, Texas 77401, United States
  • Center for Clinical Studies /ID# 213186
    Cypress, Texas 77433, United States
  • Dermatology Treatment and Research Center, PA /ID# 205473
    Dallas, Texas 75230, United States
  • Epiphany Dermatology - Fort Worth /ID# 210073
    Fort Worth, Texas 76244-6548, United States
  • Styde Research, LLC /ID# 213469
    Lewisville, Texas 75067, United States
  • Austin Institute for Clinical Research /ID# 206640
    Pflugerville, Texas 78660, United States
  • Derm Clin Res Ctr San Antonio /ID# 205469
    San Antonio, Texas 78229, United States
  • EPIC Medical Research /ID# 206382
    Murray, Utah 84123-5632, United States
  • Aspen Clinical Research /ID# 208399
    Orem, Utah 84058, United States
  • Timber Lane Allergy & Asthma Research, LLC /ID# 206897
    South Burlington, Vermont 05403-7204, United States
  • The Education & Research Foundation, Inc. /ID# 206900
    Lynchburg, Virginia 24501-1403, United States
  • Bellingham Asthma Allergy and Immunology Clinic /ID# 210357
    Bellingham, Washington 98225-1945, United States
  • Clinical Investigation Specialist, Inc - Kenosha /ID# 215933
    Kenosha, Wisconsin 53144-1782, United States
  • The Skin Hospital /ID# 217846
    Westmead, New South Wales 2145, Australia
  • The Skin Centre /ID# 205922
    Benowa, Queensland 4217, Australia
  • Box Hill Hospital /ID# 206023
    Box Hill, Victoria 3128, Australia
  • Monash Children's Hospital /ID# 217917
    Clayton, Victoria 3168, Australia
  • Sinclair Dermatology /ID# 217791
    East Melbourne, Victoria 3002, Australia
  • The Royal Melbourne Hospital /ID# 205919
    Parkville, Victoria 3050, Australia
  • Murdoch Children's Research Institute /ID# 205667
    Parkville, Victoria 3052, Australia
  • Universitaetsklinikum St. Poelten /ID# 206909
    Sankt Pölten, Lower Austria 3100, Austria
  • Klinik Donaustadt /ID# 206572
    Vienna, State of Vienna 1220, Austria
  • Ordensklinikum Linz GmbH Elisabethinen /ID# 206573
    Linz, Upper Austria 4010, Austria
  • Landeskrankenhaus Salzburg-Universitätsklinikum der PMU (LKH) /ID# 208281
    Salzburg, 5020, Austria
  • UCL Saint-Luc /ID# 205537
    Woluwe-Saint-Lambert, Brussels Capital 1200, Belgium
  • UZ Gent /ID# 205181
    Ghent, Oost-Vlaanderen 9000, Belgium
  • Centre Hospitalier Universitaire du Sart Tilman CHU de Liege /ID# 204938
    Liège, 4000, Belgium
  • Medical center Sveti Panteleimon /ID# 210414
    Sofia, 1000, Bulgaria
  • Acibadem City Clinic Tokuda University Hospital EAD /ID# 205292
    Sofia, 1407, Bulgaria
  • Military Medical Academy Multiprofile Hospital /ID# 205291
    Sofia, 1606, Bulgaria
  • Medical complex Doverie /ID# 211289
    Sofia, 1632, Bulgaria
  • Stratica Medical /ID# 205415
    Edmonton, Alberta T5K 1X3, Canada
  • Alberta DermaSurgery Centre /ID# 205422
    Edmonton, Alberta T6G 1C3, Canada
  • UBC Department of Dermatology and Skin Science The Skin Care Centre /ID# 207837
    Vancouver, British Columbia V5Z 4E8, Canada
  • Pacific Derm /ID# 206797
    Vancouver, British Columbia V6H 4E1, Canada
  • Skin Care Studio /ID# 205420
    St. John's, Newfoundland and Labrador A1E 1V4, Canada
  • SimcoDerm Medical and Surgical Dermatology Center /ID# 206333
    Barrie, Ontario L4M 7G1, Canada

Showing the first 100 of 196 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Silverberg JI, Prajapati VH, Abraham S, Irvine AD, Gooderham MJ, Guttman-Yassky E, Tanizaki H, Rademaker M, Chen SH, Moreira A, Ta R, Lee WJ, Eyerich K. Achieving Minimal Disease Activity in Atopic Dermatitis Is Associated with Fewer Flares, Reduced Healthcare Resource Utilization, and Improved Disease Control: Analysis from the Real-World MEASURE-AD Study. Dermatol Ther (Heidelb). 2026 Jul 30. doi: 10.1007/s13555-026-01865-0. Online ahead of print. PubMed 42530735 ↗
  • Eyerich K, Mendes-Bastos P, Holzer G, Jain V, Katoh N, Luna PC, Segura PC, Lane M, Grada A, Moreira A, Bunick CG. Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region. Dermatol Ther (Heidelb). 2026 Jul;16(7):3461-3477. doi: 10.1007/s13555-026-01793-z. Epub 2026 May 24. PubMed 42177735 ↗
  • Irvine AD, Prajapati VH, Guttman-Yassky E, Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Gold LFS, de Bruin-Weller M, Bieber T, Kabashima K, Rosmarin D, Sancho C, Calimlim BM, Grada A, Yang Y, Wu X, Levy G, Raymundo EM, Teixeira HD, Silverberg JI. Efficacy and Safety of Upadacitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 3 Randomized Clinical Trial Results Through 140 Weeks. Am J Clin Dermatol. 2025 Nov;26(6):1003-1016. doi: 10.1007/s40257-025-00975-3. Epub 2025 Sep 3. PubMed 40900410 ↗
  • Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E. Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. Adv Ther. 2025 Oct;42(10):5215-5237. doi: 10.1007/s12325-025-03328-y. Epub 2025 Aug 28. PubMed 40875187 ↗
  • Silverberg JI, Gooderham M, Katoh N, Aoki V, Pink AE, Binamer Y, Glick B, Staubach P, Calimlim B, Li C, Grada A, Moreira A, Lee WJ, Wollenberg A. Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2). Dermatol Ther (Heidelb). 2025 Sep;15(9):2583-2594. doi: 10.1007/s13555-025-01485-0. Epub 2025 Jul 14. PubMed 40658277 ↗
  • Simpson EL, Silverberg JI, Prajapati VH, Eyerich K, Katoh N, Boguniewicz M, Guttman-Yassky E, Song EJ, Lee WJ, Teixeira HD, Wu T, Sancho Sanchez C, Vigna N, Calimlim BM, de Bruin-Weller M. Rapid Itch Improvement and Skin Clearance with Upadacitinib Versus Placebo (Measure Up 1 and Measure Up 2) and Versus Dupilumab (Heads Up): Results from Three Phase 3 Clinical Trials in Patients with Moderate-to-Severe Atopic Dermatitis. Dermatol Ther (Heidelb). 2025 Aug;15(8):2061-2076. doi: 10.1007/s13555-025-01443-w. Epub 2025 Jun 2. PubMed 40457140 ↗
  • Paller AS, Mendes-Bastos P, Siegfried E, Eichenfield LF, Soong W, Prajapati VH, Lio P, Simpson EL, Raymundo EM, Suravaram S, Hu X, Yang Y, Huang X, Calimlim BM, Platt AM, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Upadacitinib in Adolescents With Moderate to Severe Atopic Dermatitis: Analysis of 3 Phase 3 Randomized Clinical Trials Through 76 Weeks. JAMA Dermatol. 2024 Dec 1;160(12):1304-1313. doi: 10.1001/jamadermatol.2024.3696. PubMed 39441580 ↗
  • Blauvelt A, Eyerich K, Irvine AD, de Bruin-Weller M, Kwatra SG, Gooderham M, Kim B, Calimlim BM, Lee WJ, Raymundo EM, Liu Y, Ofori S, Platt AM, Silverberg JI. More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis. Dermatol Ther (Heidelb). 2024 Sep;14(9):2621-2630. doi: 10.1007/s13555-024-01242-9. Epub 2024 Aug 7. PubMed 39110139 ↗
  • Simpson EL, Prajapati VH, Leshem YA, Chovatiya R, de Bruin-Weller MS, Stander S, Pink AE, Calimlim BM, Lee WJ, Teixeira H, Ladizinski B, Hu X, Yang Y, Liu Y, Liu M, Grada A, Platt AM, Silverberg JI. Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2). Dermatol Ther (Heidelb). 2024 May;14(5):1127-1144. doi: 10.1007/s13555-024-01157-5. Epub 2024 May 2. PubMed 38696027 ↗
  • Silverberg JI, Gooderham MJ, Paller AS, Deleuran M, Bunick CG, Gold LFS, Hijnen D, Calimlim BM, Lee WJ, Teixeira HD, Hu X, Zhang S, Yang Y, Grada A, Platt AM, Thaci D. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2). Am J Clin Dermatol. 2024 May;25(3):485-496. doi: 10.1007/s40257-024-00853-4. Epub 2024 Mar 25. PubMed 38528257 ↗
  • Thyssen JP, Thaci D, Bieber T, Gooderham M, de Bruin-Weller M, Soong W, Kabashima K, Barbarot S, Luna PC, Xu J, Hu X, Liu Y, Raymundo EM, Calimlim BM, Nduaka C, Gamelli A, Simpson EL. Upadacitinib for moderate-to-severe atopic dermatitis: Stratified analysis from three randomized phase 3 trials by key baseline characteristics. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1871-1880. doi: 10.1111/jdv.19232. Epub 2023 Jun 21. PubMed 37247226 ↗
  • Paller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, Lio P, Thyssen JP, Simpson EL, Platt AM, Raymundo EM, Liu J, Calimlim BM, Huang X, Gu Y, Hu X, Yang Y, Su JC, Zheng M, Yamamoto-Hanada K, Teixeira HD, Irvine AD. Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis: Analysis of the Measure Up 1, Measure Up 2, and AD Up Randomized Clinical Trials. JAMA Dermatol. 2023 May 1;159(5):526-535. doi: 10.1001/jamadermatol.2023.0391. PubMed 37043227 ↗
  • Burmester GR, Cohen SB, Winthrop KL, Nash P, Irvine AD, Deodhar A, Mysler E, Tanaka Y, Liu J, Lacerda AP, Palac H, Shaw T, Mease PJ, Guttman-Yassky E. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023 Feb;9(1):e002735. doi: 10.1136/rmdopen-2022-002735. PubMed 36754548 ↗
  • Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, Jiang P, Liu J, Prajapati VH, Simpson EL, Vigna N, Teixeira HD, Barbarot S. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022 Oct;87(4):784-791. doi: 10.1016/j.jaad.2022.06.012. Epub 2022 Jun 15. PubMed 35714786 ↗
  • Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N, Calimlim BM, Thyssen JP, Chiou AS, Bissonnette R, Stein Gold LF, Wegzyn C, Hu X, Liu M, Liu J, Tenorio AR, Chu AD, Guttman-Yassky E. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. JAMA Dermatol. 2022 Apr 1;158(4):404-413. doi: 10.1001/jamadermatol.2022.0029. PubMed 35262646 ↗
  • Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, Thaci D, Chu CY, Hong HC, Katoh N, Paller AS, Calimlim B, Gu Y, Hu X, Liu M, Yang Y, Liu J, Tenorio AR, Chu AD, Irvine AD. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021 Jun 5;397(10290):2151-2168. doi: 10.1016/S0140-6736(21)00588-2. Epub 2021 May 21. PubMed 34023008 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Mar 2021, 31 months.

Results were first posted in Mar 2022, 1 year after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 31 months is above that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2018
First posted
Jul 31, 2018
StartActual
Jul 27, 2018
Primary completionActual
Mar 11, 2021
CompletionActual
Nov 11, 2025
Results first posted
Mar 28, 2022
Last update
Jun 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03607422
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 31, 2018
Start date
Jul 27, 2018
Primary completion
Mar 11, 2021
Completion
Nov 11, 2025
Results posted
Mar 28, 2022
Last update
Jun 2, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion